COMPANY
BioCorRx
Timeline
- Trial start Phase 1: Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04828694 | Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections | Phase 1 | Completed | Jun 17, 2022 | Feb 22, 2023 (actual) |
NIH awards 6
- NIH award 5U01DA059994-02 FY2025: $3,274,441 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DEVARNEY, KATHERINE BEEBE; recipient as written: BIOCORRX PHARMACEUTICALS INC, ANAHEIM, CA. Efficacy, safety, an source ↗
- NIH award 1U01DA059994-01 FY2024: $4,131,123 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DEVARNEY, KATHERINE BEEBE; recipient as written: BIOCORRX PHARMACEUTICALS INC, ANAHEIM, CA. Efficacy, safety, an source ↗
- NIH award 3UH3DA047925-03S1 FY2022: $99,431 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI MALLON, ANDREW PETER; recipient as written: BIOCORRX, INC., ANAHEIM, CA. Development of a 3-month implantable dep source ↗
- NIH award 4UH3DA047925-03 FY2021: $3,453,367 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI DEVARNEY, KATHERINE BEEBE; recipient as written: BIOCORRX, INC., ANAHEIM, CA. Development of a 3-month implantab source ↗
- NIH award 5UG3DA047925-02 FY2020: $2,831,838 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI MALLON, ANDREW PETER; recipient as written: BIOCORRX, INC., ANAHEIM, CA. Development of a 3-month implantable de source ↗
- NIH award 1UG3DA047925-01 FY2019: $2,842,430 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI BRAR, BALBIR; recipient as written: BIOCORRX, INC., ANAHEIM, CA. Development of a 3-month implantable depot pell source ↗